Testing the right target and right drug at the right stage

Area of Science:

• Neuroscience
• Neurology
• Pharmacology

Background:

• Alzheimer's disease (AD) is a leading cause of death with no current disease-modifying therapies.
• Recent clinical trials for AD have yielded disappointing results, particularly in the dementia stage.
• Growing evidence indicates AD's pathological processes initiate years prior to clinical dementia onset.

Purpose of the Study:

• To question the current strategy of testing early-stage AD drugs in late-stage dementia patients.
• To highlight the critical need to align therapeutic targets with the disease's preclinical and early symptomatic phases.
• To advocate for a paradigm shift in AD drug development towards earlier intervention.

Main Methods:

• Review of current Alzheimer's disease drug development approaches.
• Analysis of trial outcomes in relation to disease stage.
• Synthesis of evidence on the preclinical and early symptomatic stages of AD pathophysiology.

Main Results:

• Current approaches often test disease-modifying agents in patients with advanced dementia.
• This timing may be too late for therapies targeting early pathological events.
• The efficacy of interventions is likely compromised by testing at the end-stage of the illness.

Conclusions:

• Drug development for Alzheimer's disease needs re-evaluation.
• Testing therapies in earlier disease stages is crucial for success.
• A focus on preclinical or mild cognitive impairment stages may improve therapeutic outcomes.